Backed by mounting scientific data on the curative effects of CBDs, specialty biotech companies like InMed Pharmaceuticals, Inc. (CSE: IN) (OTC: IMLFF) have the opportunity to capitalize on the explosive growth expected in the cannabis-derived pharmaceutical market.
